Clinical Trials Sponsored by AmpliMed Corporation

Total 7111 results

AmpliMed Corporation

Completed

A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer

Pancreatic Neoplasms

United States
AmpliMed Corporation

Withdrawn

A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
AmpliMed Corporation

Completed

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Malignant Melanoma

United States
AmpliMed Corporation

Completed

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
AmpliMed Corporation

Completed

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

Multiple Myeloma

United States
AmpliMed Corporation

Completed

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

Breast Cancer | Prostate Cancer | Non-small Cell Lung Cancer

United States
AmpliMed Corporation

Completed

Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy

Neoplasm Metastasis

United States
GenMont Biotech Incorporation
Biomedical Development Corporation

Completed

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PAR)

Probiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)

Taiwan
Apnimed

Not yet recruiting

Study That Tests AD109 in Patients Taking GLP-1 Drugs

OSA

United States
Apnimed

Completed

Crossover Trial of AD036 in Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Apnimed

Completed

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) (SEED)

Obstructive Sleep Apnea

United States
Apnimed

Completed

Trial of AD036 in Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Apnimed

Completed

Parallel Arm Trial of AD109 and AD504 In Patients With OSA (MARIPOSA)

OSA - Obstructive Sleep Apnea

United States
Apnimed

Completed

Crossover Trial of AD182 and AD504 in Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Apnimed

Completed

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Hypertension | Obstructive Sleep Apnea

United States
Apnimed

Completed

Crossover Trial of AD109 in Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Apnimed

Recruiting

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

OSA

United States, Canada
Apnimed

Active, not recruiting

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

OSA

United States
Apnimed

Completed

AD816 Crossover Study (VicTor)

Obstructive Sleep Apnea | OSA

United States
Apnimed

Completed

AD109 Dose Finding in Mild to Moderate OSA

Obstructive Sleep Apnea

United States
Rgene Corporation
American BriVision Corporation

Not yet recruiting

Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy

Nonsquamous Nonsmall Cell Neoplasm of Lung

Taiwan
Rgene Corporation
American BriVision Corporation

Not yet recruiting

A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer

Pancreatic Cancer
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA Modul 7 VRR

Atrial Fibrillation

Germany
Boston Scientific Corporation
EKOS Corporation

Completed

ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism (ULTIMA)

Submassive Pulmonary Embolism

Germany, Switzerland
Boston Scientific Corporation
EKOS Corporation

Completed

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism (OPTALYSE PE)

Pulmonary Embolism and Thrombosis

United States, United Kingdom
Boston Scientific Corporation
EKOS Corporation

Completed

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy (SEATTLE II)

Pulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary Embolism

United States
Boston Scientific Corporation
Guidant Corporation

Completed

MODULA Modul 5 BEAT-HF

Heart Failure

Germany
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms

Heart Failure

Germany
Guidant Corporation
Boston Scientific Corporation

Completed

Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following (Cogent-4)

Heart Failure | Ventricular Tachycardia, Ventricular Fibrillation

Israel, Denmark
Boston Scientific Corporation
EKOS Corporation

Withdrawn

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Coronary Artery Disease | Atherosclerosis | Peripheral Artery Disease | Chronic Total Occlusion

United States
Boston Scientific Corporation
EKOS Corporation

Completed

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System (ACCESS PTS)

Deep Vein Thrombosis | Post-thrombotic Syndrome

United States
Guidant Corporation
Boston Scientific Corporation

Completed

Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device (SEPTAL-CRT)

Ventricular Fibrillation | Ventricular Tachycardia | Systolic Heart Failure

France, Spain
Boston Scientific Corporation
Guidant Corporation

Completed

Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead

Ventricular Fibrillation | Ventricular Tachycardia

France
Boston Scientific Corporation
Guidant Corporation

Completed

Shockless Implant Evaluation (SIMPLE)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Spain, Canada, Israel, Netherlands, France, Finland, United Kingdom, Austria, Malaysia, Thailand, Hong Kong, Sweden, Hungary, Australia, Czechia, Norway, Poland
Boston Scientific Corporation
Guidant Corporation

Completed

Feature Assessment Study for Indications Based Programming (FASt-IBP)

Heart Failure | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Flutter

Germany, Spain, Switzerland, China, Austria, Belgium, France, Greece, Latvia, Netherlands, Slovakia
Boston Scientific Corporation
Guidant Corporation

Completed

Japanese Assessment of Indication Based Programming (JASMINE)

Heart Failure | Arrhythmias, Cardiac

Japan
Boston Scientific Corporation
Guidant Corporation

Completed

Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ? (Quick ICD)

Cardiac Arrest

Germany
Applied Biology, Inc.

Completed

Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002

Alopecia | Hair Diseases | Hair Loss

Brazil
Applied Therapeutics, Inc.

Active, not recruiting

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency (INSPIRE)

Hereditary Neuropathy Caused by SORD Deficiency

United States, United Kingdom, Czechia, Italy
TASK Applied Science

Completed

Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

Pulmonary Tuberculosis

South Africa
Applied Therapeutics, Inc.

Active, not recruiting

AT-007 in Adult Subjects With Classic Galactosemia (CG)

Classic Galactosemia

United States
Applied Biology, Inc.

Withdrawn

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

Covid19 | SARS (Severe Acute Respiratory Syndrome)

Brazil
TASK Applied Science

Completed

Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB (TB_COMBO_01)

Tuberculosis

South Africa
Applied Biology, Inc.

Completed

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

Breast Cancer | Sexual Dysfunction | Sexual Dysfunction, Physiological | Neuropathy | Cancer of Breast | Sexual Arousal Disorder | Nipple Disorder

United States
Shanghai Antengene Corporation Limited

Terminated

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors (REACH)

Advanced Solid Tumors

China
Mitsubishi Tanabe Pharma Corporation
Kureha Corporation

Completed

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

Chronic Kidney Disease

United States, France, Italy, Ukraine, Argentina, Mexico, Poland, Canada, Brazil, Russian Federation, Czechia, Puerto Rico
Mitsubishi Tanabe Pharma Corporation
Kureha Corporation

Completed

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

Chronic Kidney Disease

United States, Poland, Ukraine, Spain, Argentina, Mexico, Canada, Brazil, Russian Federation, Puerto Rico, Germany, Czechia
TASK Applied Science

Recruiting

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098 (BETO)

Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)

South Africa
Applied Therapeutics, Inc.

Active, not recruiting

Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia

Classic Galactosemia

United States
Applied Molecular Transport

Completed

Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis (FILLMORE)

Pouchitis

United States, Canada, France, Spain, United Kingdom, Germany, Belgium, Hungary, Netherlands, Switzerland

Clinical Trials Sponsored by AmpliMed Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations